| Species |
Human |
| Protein Construction |
| hFc |
Galectin 1 (Ala2-Asp135)
Accession # P09382 |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Galectin 1 hFc Chimera, Human at 1μg/ml (100μl/Well) on the plate can bind Biotinylated AntiGalectin 1 Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
41.9 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 48-55 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Galectin 1(Gal-1), a β-galactoside binding mammalian lectin of 14KDa, is implicated in many signalling pathways, immune responses associated with cancer progression and immune disorders. Inhibition of human Gal-1 has been regarded as one of the potential therapeutic approaches for the treatment of cancer, as it plays a major role in tumour development and metastasis by modulating various biological functions viz. apoptosis, angiogenesis, migration, cell immune escape. |
| Synonyms |
Galectin-1; HLBP14; S-Lac lectin 1; LGALS1; GAL1; GBP; DKFZp686E23103; Galectin 1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
